Expression of NEDD9 in hepatocellular carcinoma and its clinical significance

Oncology Reports

Volumn 33, Issue 5, 2015, Pages 2375-2383

  Lu, Peng ^a,b   Wang, Zhi Peng ^b   Dang, Zheng ^c   Zheng, Zhi Gang ^a   Li, Xiao ^a   Zhou, Liang ^d   Ding, Rui ^a   Yue, Shu Qiang ^a   Dou, Ke Feng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c LANZHOU GENERAL HOSPITAL   (China)

^d 155 Central Hospital of PLA   (China)

Author keywords

Clinicopathological factors; Hepatocellular carcinoma; NEDD9; Prognosis; Survival

Indexed keywords

ALPHA FETOPROTEIN; LIGASE; NEDD9 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; MESSENGER RNA; NEDD9 PROTEIN, HUMAN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEDD9 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; LIVER VEIN; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATIC VEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PHOSPHOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84927138090     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3863     Document Type: Article

References (30)

1. Nordenstedt H, White DL and El-Serag HB: The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42(Suppl 3):S206-S214, 2010.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005.
3. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma: Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 25:657-663, 2010.
4. Yuen MF, Hou JL, Chutaputti A; Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma: Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 24:346-353, 2009.
5. Schwartz ME and Shrager B: Surgical resection for hepatocellular carcinoma in the noncirrhotic: the Western experience. Recent Results Cancer Res 190:85-100, 2013.
6. Yang Y, Nagano H, Ota H, et al: Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 141:196-202, 2007.
7. Tang ZY, Ye SL, Liu YK, et al: A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130:187-196, 2004.
8. Yang LY, Tao YM, Ou DP, Wang W, Chang ZG and Wu F: Increased expression of Wiskott-Aldrich syndrome protein family verprolin-homologous protein 2 correlated with poor prognosis of hepatocellular carcinoma. Clin Cancer Res 12:5673-5679, 2006.
9. Okuda K: Hepatocellular carcinoma: clinicopathological aspects. J Gastroenterol Hepatol 12:S314-S318, 1997.
10. Tandon P and Garcia-Tsao G: Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 29:502-510, 2009.
11. Di Bisceglie AM: Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 127(Suppl 1):S104-S107, 2004.
12. Daniele B, Bencivenga A, Megna AS and Tinessa V: α-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127(Suppl 1):S108-S112, 2004.
13. Farinati F, Marino D, De Giorgio M, et al: Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 101:524-532, 2006.
14. Minegishi M, Tachibana K, Sato T, Iwata S, Nojima Y and Morimoto C: Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in β1 integrin-mediated signaling in lymphocytes. J Exp Med 184:1365-1375, 1996.
15. Law SF, Estojak J, Wang B, Mysliwiec T, Kruh G and Golemis EA: Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol 16:3327-3337, 1996.
16. Kumar S, Tomooka Y and Noda M: Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun 185:1155-1161, 1992.
17. Tikhmyanova N, Little JL and Golemis EA: CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci 67:1025-1048, 2010.
18. Minn AJ, Gupta GP, Siegel PM, et al: Genes that mediate breast cancer metastasis to lung. Nature 436:518-524, 2005.
19. Natarajan M, Stewart JE, Golemis EA, et al: HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene 25:1721-1732, 2006.
20. Kim M, Gans JD, Nogueira C, et al: Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269-1281, 2006.
21. Xue YZ, Sheng YY, Liu ZL, et al: Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance. Tumour Biol 34:895-899, 2013.
22. Guerrero MS, Parsons JT and Bouton AH: Cas and NEDD9 contribute to tumor progression through dynamic regulation of the cytoskeleton. Genes Cancer 3:371-381, 2012.
23. Astier A, Manié SN, Law SF, et al: Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. Leuk Lymphoma 28:65-72, 1997.
24. Lucas JT Jr, Salimath BP, Slomiany MG and Rosenzweig SA: Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene 29:4449-4459, 2010.
25. Kong C, Wang C, Wang L, et al: NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One 6:e22666, 2011.
26. Tikhmyanova N and Golemis EA: NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS One 6:e22102, 2011.
27. Thaole B, Vu HA, Yasuda K, et al: Cas-L was over-expressed in imatinib-resistant gastrointestinal stromal tumor cells. Cancer Biol Ther 8:683-688, 2009.
28. Nagasue N: Liver resection for hepatocellular carcinoma: indications, techniques, complications, and prognostic factors. J Hepatobiliary Pancreat Surg 5:7-13, 1998.
29. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC and Hsu HC: High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and β-catenin mutations. Int J Cancer 112:44-50, 2004.
30. Trevisani F, D'Intino PE, Morselli-Labate AM, et al: Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34:570-575, 2001.